Outcomes following mepolizumab treatment discontinuation: Real-world experience from an open-label trial

Hector Ortega, Catherine Lemiere, Jean Pierre Llanos, Mark Forshag, Robert Price, Frank Albers, Steven Yancey, Mario Castro

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Limited information is available on the clinical course of patients with severe asthma following discontinuation of biologic treatment. Therefore, a post hoc analysis was conducted in patients with severe eosinophilic asthma who participated in the COSMOS trial, where patients received mepolizumab for more than 1 year of continuous therapy. The objective of this post hoc analysis was to evaluate changes in the Asthma Control Questionnaire (ACQ-5) and blood eosinophil counts 12 weeks after the last administration of mepolizumab. Cessation of mepolizumab was associated with a rise in the blood eosinophil count and loss of asthma control after stopping therapy. These data suggest that patients with severe disease require extended and continuous treatment. Further studies evaluating longer duration of continuous treatment with mepolizumab could help understanding of whether changes in the presentation of the disease (disease modification) are possible with the use of biologics, such as mepolizumab.

Original languageEnglish
Article number37
JournalAllergy, Asthma and Clinical Immunology
Issue number1
StatePublished - Jun 10 2019


  • Asthma control
  • Blood eosinophils
  • Cessation of treatment
  • Severe eosinophilic asthma


Dive into the research topics of 'Outcomes following mepolizumab treatment discontinuation: Real-world experience from an open-label trial'. Together they form a unique fingerprint.

Cite this